|
- Depending on a number of parameters, an antibody that is reactive in an ELISA usually also performs in immunoblot (Western) assays using overexpressed protein. However, this is not always the case. If specific performance properties from the monoclonal or polyclonal antibodies, such as reactivity in immunoblots, ability to fix complement, absence of “stickiness” (unusual glycosylation in the Fc region), ability to bind to native (folded) antigen or a specific epitope, etc. are required, then the client should discuss such needs in detail with Dr. Lai prior to initiation of work. In general, the Core can only guarantee that the antibody provided will be reactive against the original antigen in its original state.
- Please note that for polyclonals, the Core shall deliver to the client antisera that is ELISA-positive with respect to the immunizing antigen.
- Please note that for monoclonals, the Core shall deliver to the client cell line(s) that are ELISA-positive with respect to the immunizing antigen. Dr. Lai can advise the client in the design screens that will enhance the likelihood of identifying a hybridoma secreting a monoclonal antibody with a specific performance trait(s). However, any added work involved in this type of screening is out of the scope of the work conducted by the Core, and is the responsibility of the client.
- The goal of the Antibody Core Facility is to provide investigators with high quality antibodies that meet the needs of their research. Therefore, the Antibody Core Facility will not fully charge clients for antibodies that are unsuitable for their intended purpose as discussed with Dr. Lai prior to initiation of work. Acceptance of the antibody by the investigator, after it is evaluated, upon delivery must be final.
|
|
